Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 4:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 204 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Omega-3 fatty acid (Eicosapentaenoic acid) Clear all
Completed Phase 2 Interventional Results available

Polyunsaturated Fatty Acids (PUFA) in Diabetic Fatty Liver

NCT00323414
View directory record Official record
Conditions
Fatty Liver
Interventions
Polyunsaturated fatty acid (Opti-EPA), Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 14, 2026, 4:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Placebo Controlled Double Masked Clinical Assessment Study of Essential Fatty Acid Supplement and Its Effect on Patients With Apparent Aqueous Deficient Dry Eye Syndrome

NCT00344721
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
Omega-3 fatty acid supplement, Placebo
Dietary Supplement
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Oct 14, 2026, 4:55 AM EDT
Completed Phase 2 Interventional

Taxoprexin® Treatment for Advanced Eye Melanoma

NCT00244816
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Taxoprexin
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
13 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 14, 2026, 4:55 AM EDT
Completed Not applicable Interventional

Use of Formula Fortified With DHA in Infants With Cystic Fibrosis

NCT00530244
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Docosahexaenoic acid (DHA), Standard formula (Enfamil)
Dietary Supplement
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
Up to 56 Days
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
24
States / cities
Birmingham, Alabama • Atlanta, Georgia • Des Moines, Iowa + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2018 · Synced Oct 14, 2026, 4:55 AM EDT
Terminated Phase 2 Interventional

Taxoprexin® Treatment for Advanced Primary Cancers of the Liver, Gallbladder or Biliary Tract

NCT00422877
View directory record Official record
Conditions
Cancer of the Liver
Interventions
Taxoprexin
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 14, 2026, 4:55 AM EDT
Completed Phase 2 Interventional

Omega-3 Fatty Acids in the Treatment of Bipolar Disorder: A Double-Blind, Placebo-Controlled Trial

NCT00001146
View directory record Official record
Conditions
Bipolar Disorder, Involutional Depression, Mood Disorder
Interventions
Ethyl Eicosapentaenoic Acid, OmegaBrite
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 14, 2026, 4:55 AM EDT
Withdrawn Phase 4 Interventional

A PET Study With [11C]PBR-28 and an Experimental Medication, Ethyl Eicosapentaenoic Acid

NCT04811404
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Ethyl Eicosapentaenoic Acid
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2022 · Synced Oct 14, 2026, 4:55 AM EDT
Completed Not applicable Interventional Results available

Effect of EPA and HMB on Strength in ICU Patients

NCT01270516
View directory record Official record
Conditions
Muscle Weakness
Interventions
HMB, hydroxymethylbutyrate, EPA, eicosapentaenoic acid, Saline
Drug
Lead sponsor
Gerald Supinski
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Oct 14, 2026, 4:55 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body

NCT05198843
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Inflammatory Carcinoma
Interventions
Dasatinib, Icosapent Ethyl
Drug · Dietary Supplement
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Oct 14, 2026, 4:55 AM EDT
Completed Phase 3 Interventional

Effect of 8-Week Dietary DHA Supplementation on Cerebral Blood Flow and Metabolic Function

NCT00662142
View directory record Official record
Conditions
Healthy, Attention
Interventions
docosahexaenoic acid
Dietary Supplement
Lead sponsor
University of Cincinnati
Other
Eligibility
8 Years to 10 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 17, 2013 · Synced Oct 14, 2026, 4:55 AM EDT
Completed Phase 2 Interventional Results available

Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation

NCT00167310
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Major Depression, Bipolar Disorder, Coronary Artery Disease
Interventions
Eicosapentaenoic acid (omega-3 fatty acid), Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Oct 14, 2026, 4:55 AM EDT
Completed Phase 3 Interventional Results available

The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)

NCT00069784
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
insulin glargine (HOE901), omega-3 polyunsaturated fatty acids (PUFA), placebo, reusable pen device for insulin injection
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older
Enrollment
12,537 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 14, 2026, 4:55 AM EDT
Active, not recruiting Not applicable Interventional

Study on Use of Omega-3 Fatty Acids to Improve Outcomes in Individuals With Sickle Cell Disease

NCT05758766
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Plant-based omega-3-FA
Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
5 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 14, 2026, 4:55 AM EDT
Completed Not applicable Interventional

Dietary Intervention for Bipolar Disorder

NCT02272010
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Experimental Diet, Comparator Diet
Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 10, 2019 · Synced Oct 14, 2026, 4:55 AM EDT
Completed Phase 2 Interventional Results available

Vitamin E and DHA-EE on NAFLD - Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial (PUVENAFLD)

NCT04198805
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Fatty Liver, Non-Alcoholic Steatohepatitis
Interventions
Vitamin E [(all-rac)-α-tocopheryl acetate], Omega-3 fatty acid (DHA EE), Omega-3 fatty acid (DHA EE) & Vitamin E [(all-rac)-α-tocopheryl acetate], Placebo
Dietary Supplement · Combination Product · Other
Lead sponsor
Naga P. Chalasani
Other
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
15
States / cities
Chandler, Arizona • Tucson, Arizona • North Little Rock, Arkansas + 10 more
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Oct 14, 2026, 4:55 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid

NCT02719327
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
icosapent ethyl (IPE), gel cap placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years to 75 Years
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Oct 14, 2026, 4:55 AM EDT
Recruiting Not applicable Interventional

OMEGA - Dietary Intervention - COPD Trial

NCT05297279
View directory record Official record
Conditions
COPD, Chronic Obstructive Pulmonary Disease
Interventions
Home delivery Omega-3 rich Food, Dietary Motivational Coaching, Home delivery Food
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 14, 2026, 4:55 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

VITamin D and OmegA-3 TriaL: Effects on Mammographic Density and Breast Tissue

NCT02239874
View directory record Official record
Conditions
Benign Breast Disease
Interventions
Vitamin D and fish oil placebo, Fish oil and vitamin D placebo, Vitamin D placebo and fish oil placebo, Vitamin D and fish oil
Dietary Supplement
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
55 Years to 67 Years · Female only
Enrollment
3,894 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Oct 14, 2026, 4:55 AM EDT
Completed Not applicable Interventional

Genetic Effect on Omega 3 Fatty Acids for the Treatment of Fatty Liver Disease

NCT01556113
View directory record Official record
Conditions
Non Alcoholic Fatty Liver Disease, Steatohepatitis, Hypertriglyceridemia, Alanine Aminotransferase, Plasma Level of, Quantitative Trait Locus 1
Interventions
Omega diet
Other
Lead sponsor
Yale University
Other
Eligibility
10 Years to 19 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Oct 14, 2026, 4:55 AM EDT
Completed Phase 3 Interventional Results available

DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease

NCT00440050
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
DHA (Docosahexaenoic Acid), Placebo
Drug
Lead sponsor
Alzheimer's Disease Cooperative Study (ADCS)
Other
Eligibility
50 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
51
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Oct 14, 2026, 4:55 AM EDT
Completed Phase 2 Interventional

Omega-3 Fatty Acids in Bipolar Disorder

NCT00010868
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Omega-3 Fatty Acids
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
2
States / cities
Belmont, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2006 · Synced Oct 14, 2026, 4:55 AM EDT
Completed Phase 4 Interventional Results available

Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy

NCT00498368
View directory record Official record
Conditions
IgA Nephropathy
Interventions
Intravenous Rituximab, ACE/ARB, Omega-3 Fatty Acid Fish Oil Supplement
Drug · Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
5
States / cities
San Francisco, California • Rochester, Minnesota • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 14, 2026, 4:55 AM EDT
Completed Phase 1 Interventional Results available

NAPLS Omega-3 Fatty Acid Versus Placebo Study

NCT01429454
View directory record Official record
Conditions
Psychosis
Interventions
Omega-3 Long Chain Fatty Acid, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
12 Years to 30 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
8
States / cities
Los Angeles, California • San Diego, California • New Haven, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2021 · Synced Oct 14, 2026, 4:55 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

DHA Supplements to Improve Insulin Sensitivity in Obese Pregnant Women (The Omega-3 Pregnancy Study)

NCT00865683
View directory record Official record
Conditions
Overweight and Obesity, Insulin Resistance, Diabetes, Gestational, Hypertension in Pregnancy, Pre-Eclampsia
Interventions
DHA Supplements, Placebo Supplements
Dietary Supplement
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 40 Years · Female only
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 15, 2009 · Synced Oct 14, 2026, 4:55 AM EDT